1 - 10 of 37 articles
Lung transplant recipients present an increased risk for severe complications associated with respiratory infections. We conducted a review of the literature examining the clinical relationship between viral respiratory infection and graft complications. Thirty‐four studies describing the...
This month, “The AJT Report” reviews the NIH's renewed funding support for several xenotransplantation research groups, and what it may mean for the future of the field. We also explore what an edict issued last fall by London's Chief Rabbi may mean for organ donation and transplantation in the...
The factors that regulate beta cell growth have remained elusive. Two recent reports define new receptors and ligands that influence beta cell proliferation, growth, mass and function, which may prove important for improving the success of islet transplantation.
The regulatory framework guiding the approval of therapies for antibody‐mediated rejection is complex, and collaboration between the scientific community and the FDA will be required to facilitate registration trials for this indication. See meeting report by Archdeacon et al on page 896.
The implications of a new murine orthotopic lung transplantation model for bronchiolitis obliterans are considered in light of other experimental models. See article by Fan et al on page 911.
Organ acceptance decisions are made by individuals and reflect detailed knowledge of recipient disease severity and donor quality within the context of a local environment and center practice. See article by Volk et al on page 958.
Combined tacrolimus and mycophenolate for liver transplant immunosuppression achieves better outcomes than tacrolimus alone, based on a new randomized, controlled trial. See article by Boudjema et al on page 965.
Post‐transplant lymphoproliferative disorder (PTLD) is a spectrum of major, life‐threatening lymphoproliferative diseases occurring in the post‐transplant setting. The majority of PTLD is of B‐cell origin and is associated with several risk factors, the most significant being Epstein‐Barr virus...
The Food and Drug Administration (FDA) held an open public workshop in June 2010 to discuss the current state of science related to antibody‐mediated rejection (AMR) in kidney transplantation. Desensitization, acute AMR and chronic AMR (CAMR) were considered in the context of clinical trial...
Read and print from thousands of top scholarly journals.
Continue with Facebook
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.